DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS

References

• Masur H, Michelis MA, Greene JB et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N. Engl. J. Med.305(24), 1431–1438 (1981).
   PubMed Web of Science ®Google Scholar
• Gottlieb MS, Schroff R, Schanker HM et al.Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N. Engl. J. Med.305(24), 1425–1431 (1981).
   PubMed Web of Science ®Google Scholar
• Losina E, Schackman BR, Sadownik SN et al. Racial and sex disparities in life expectancy losses among HIV-infected persons in the United States: impact of risk behavior, late initiation, and early discontinuation of antiretroviral therapy. Clin. Infect. Dis.49(10), 1570–1578 (2009).
   PubMed Web of Science ®Google Scholar
• Lohse N, Hansen AB, Pedersen G et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann. Intern. Med.146(2), 87–95 (2007).
   PubMed Web of Science ®Google Scholar
• Gandhi RT, Zheng L, Bosch RJ et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med.7(8), pii: e1000321 (2010).
   Google Scholar
• Hatano H, Hayes TL, Dahl V et al. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J. Infect. Dis.203(7), 960–968 (2011).
   PubMed Web of Science ®Google Scholar
• Hatano H, Delwart EL, Norris PJ et al. Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. AIDS24(16), 2535–2539 (2010).
   Google Scholar
• Palmer S, Maldarelli F, Wiegand A et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA105(10), 3879–3884 (2008).
   PubMed Web of Science ®Google Scholar
• Abbott A. Therapeutic HIV vaccines show promise. Nature466(7306), 539 (2010).
   Google Scholar
• Routy JP, Nicolette C. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection. Immunotherapy2(4), 467–476 (2010).
   Google Scholar
• Jones T. Vacc-4x, a therapeutic vaccine comprised of four engineered peptides for the potential treatment of HIV infection. Curr. Opin. Investig. Drugs11(8), 964–970 (2010).
   Google Scholar
• Coffin J. Persistence, resistance, diversity: insights into the HIV-host interaction. Presented at: HIV DART 2010: Frontiers in Drug Development for Antiretroviral Therapies. Los Cabos, Mexico, 7–10 December 2010.
   Google Scholar
• Liu L, Zhong Q, Tian T, Dubin K, Athale SK, Kupper TS. Epidermal injury and infection during poxvirus immunization is crucial for the generation of highly protective T cell-mediated immunity. Nat. Med.16(2), 224–227 (2010).
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu. Rev. Immunol.15, 617–648 (1997).
   PubMed Web of Science ®Google Scholar
• Ada G. Overview of vaccines and vaccination. Mol. Biotechnol.29(3), 255–272 (2005).
   PubMed Web of Science ®Google Scholar
• Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell124(4), 677–681 (2006).
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology. Curr. Opin. Microbiol.3(5), 445–450 (2000).
   PubMed Web of Science ®Google Scholar
• Blazevic V, Mannik A, Malm M et al. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-MultiHIV DNA vaccine. AIDS Res. Hum. Retroviruses22(7), 667–677 (2006).
   PubMed Web of Science ®Google Scholar
• Malm M, Sikut R, Krohn K, Blazevic V. GTU-MultiHIV DNA vaccine results in protection in a novel P815 tumor challenge model. Vaccine25(17), 3293–3301 (2007).
   PubMed Web of Science ®Google Scholar
• Garcia F, Climent N, Assoumou L et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. J. Infect. Dis.203(4), 473–478 (2011).
   PubMed Web of Science ®Google Scholar
• Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science247(4949 Pt 1), 1465–1468 (1990).
   PubMed Web of Science ®Google Scholar
• Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature356(6365), 152–154 (1992).
   PubMed Web of Science ®Google Scholar
• Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine21(7–8), 649–658 (2003).
   PubMed Web of Science ®Google Scholar
• Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol. Res.42(1–3), 219–232 (2008).
   PubMed Web of Science ®Google Scholar
• Anderson RJ, Schneider J. Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine25(Suppl. 2), B24–B34 (2007).
   PubMed Web of Science ®Google Scholar
• Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J. Biomed. Biotechnol.2010, 174378 (2010).
   PubMedGoogle Scholar
• Stevenson FK, Ottensmeier CH, Rice J. DNA vaccines against cancer come of age. Curr. Opin. Immunol.22(2), 264–270 (2010).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Rosenberg E, Lieberman J et al. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med.340(21), 1683–1684 (1999).
   PubMed Web of Science ®Google Scholar
• Lori F, Lewis MG, Xu J et al. Control of SIV rebound through structured treatment interruptions during early infection. Science290(5496), 1591–1593 (2000).
   PubMed Web of Science ®Google Scholar
• Toke ER, Lorincz O, Somogyi E, Lisziewicz J. Rational development of a stable liquid formulation for nanomedicine products. Int. J. Pharm.392(1–2), 261–267 (2010).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Trocio J, Whitman L et al. DermaVir: a novel topical vaccine for HIV/AIDS. J. Invest. Dermatol.124(1), 160–169 (2005).
   PubMed Web of Science ®Google Scholar
• Somogyi E, Xu J, Gudics A et al. A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP+) mimicking naturally occurring HIV. Vaccine29(4), 744–753 (2011).
   PubMedGoogle Scholar
• Paavonen J, Naud P, Salmeron J et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet374(9686), 301–314 (2009).
   PubMed Web of Science ®Google Scholar
• Group TFIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med.356(19), 1915–1927 (2007).
   PubMed Web of Science ®Google Scholar
• Le Gall S, Erdtmann L, Benichou S et al. Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity8(4), 483–495 (1998).
   PubMed Web of Science ®Google Scholar
• Yang OO, Nguyen PT, Kalams SA et al. Nef-mediated resistance of human immunodeficiency virus type 1 to antiviral cytotoxic T lymphocytes. J. Virol.76(4), 1626–1631 (2002).
   PubMed Web of Science ®Google Scholar
• Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F. Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes. J. Virol.76(5), 2274–2278 (2002).
   PubMed Web of Science ®Google Scholar
• Korber B, Brander C, Haynes BF et al.HIV Molecular Immunology. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA (2008).
   Google Scholar
• Sandstrom E, Nilsson C, Hejdeman B et al. Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. J. Infect. Dis.198(10), 1482–1490 (2008).
   PubMed Web of Science ®Google Scholar
• Ellenberger D, Wyatt L, Li B et al. Comparative immunogenicity in rhesus monkeys of multi-protein HIV-1 (CRF02_AG) DNA/MVA vaccines expressing mature and immature VLPs. Virology340(1), 21–32 (2005).
   PubMed Web of Science ®Google Scholar
• Fischer W, Perkins S, Theiler J et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med.13(1), 100–106 (2007).
   PubMed Web of Science ®Google Scholar
• Montefiori DC, Safrit JT, Lydy SL et al. Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques. J. Virol.75(13), 5879–5890 (2001).
   PubMed Web of Science ®Google Scholar
• Bellier B, Huret C, Miyalou M et al. DNA vaccines expressing retrovirus-like particles are efficient immunogens to induce neutralizing antibodies. Vaccine27(42), 5772–5780 (2009).
   PubMedGoogle Scholar
• Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol.27(12), 573–579 (2006).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Gabrilovich DI, Varga G et al. Induction of potent human immunodeficiency virus type 1-specific T-cell-restricted immunity by genetically modified dendritic cells. J. Virol.75(16), 7621–7628 (2001).
   PubMed Web of Science ®Google Scholar
• Boussif O, Lezoualc’h F, Zanta MA et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl Acad. Sci. USA92(16), 7297–7301 (1995).
   PubMed Web of Science ®Google Scholar
• Choosakoonkriang S, Lobo BA, Koe GS, Koe JG, Middaugh CR. Biophysical characterization of PEI/DNA complexes. J. Pharm. Sci.92(8), 1710–1722 (2003).
   PubMed Web of Science ®Google Scholar
• von Harpe A, Petersen H, Li Y, Kissel T. Characterization of commercially available and synthesized polyethylenimines for gene delivery. J. Control Release69(2), 309–322 (2000).
   PubMed Web of Science ®Google Scholar
• Ohana P, Gofrit O, Ayesh S et al. Regulatory sequences of the H19 gene in DNA based therapy of bladder cancer. Gene Ther. Mol. Biol.8, 181–192 (2004).
   Google Scholar
• Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med.363(5), 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods31(3), 232–242 (2003).
   PubMed Web of Science ®Google Scholar
• Zinkernagel RM. Localization dose and time of antigens determine immune reactivity. Semin. Immunol.12(3), 163–171; discussion 257–344 (2000).
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol.9, 271–296 (1991).
   PubMed Web of Science ®Google Scholar
• Matzinger P. The danger model: a renewed sense of self. Science296(5566), 301–305 (2002).
   PubMed Web of Science ®Google Scholar
• Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines7(8), 1201–1214 (2008).
   PubMed Web of Science ®Google Scholar
• Bauer J, Bahmer FA, Worl J, Neuhuber W, Schuler G, Fartasch M. A strikingly constant ratio exists between Langerhans cells and other epidermal cells in human skin. A stereologic study using the optical disector method and the confocal laser scanning microscope. J. Invest. Dermatol.116(2), 313–318 (2001).
   PubMedGoogle Scholar
• Porgador A, Irvine KR, Iwasaki A, Barber BH, Restifo NP, Germain RN. Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. J. Exp. Med.188(6), 1075–1082 (1998).
   PubMed Web of Science ®Google Scholar
• Powles T, Robinson D, Stebbing J et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J. Clin. Oncol.27(6), 884–890 (2009).
   PubMed Web of Science ®Google Scholar
• Uglietti A, Maserati R. Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411. Expert Opin. Investig. Drugs20(4), 559–565 (2011).
   PubMed Web of Science ®Google Scholar
• Calarota SA, Weiner DB, Lori F, Lisziewicz J. Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine. Vaccine25(16), 3070–3074 (2007).
   PubMed Web of Science ®Google Scholar
• Cristillo AD, Lisziewicz J, He L et al. HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3. Virology366(1), 197–211 (2007).
   PubMed Web of Science ®Google Scholar
• Calarota SA, Foli A, Maserati R et al. HIV-1-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J. Immunol.180(9), 5907–5915 (2008).
   PubMed Web of Science ®Google Scholar
• Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet372(9653), 1881–1893 (2008).
   PubMed Web of Science ®Google Scholar
• Keating SM, Bejon P, Berthoud T et al. Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J. Immunol.175(9), 5675–5680 (2005).
   PubMed Web of Science ®Google Scholar
• Schnuriger A, Dominguez S, Guiguet M et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS23(16), 2079–2089 (2009).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Trocio J, Xu J et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS19(1), 35–43 (2005).
   PubMed Web of Science ®Google Scholar
• Lisziewicz J, Calarota S, Banhegyi D, Lisziewicz Z, Ujhelyi E, Lori F. Single DermaVir patch treatment of HIV+ individuals induces long lasting, high magnitude and broad HIV-specific T cell responses. Presented at: CROI 2008. Boston, USA, 3–6 February 2008.
   Google Scholar
• Lisziewicz J, Calarota S, Banhegyi D, Lisziewicz Z, Ujhelyi E, Lori F. Single DermaVir patch treatment of HIV+ individuals induces long-lasting, high-magnitude, and broad HIV- specific T cell responses. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3–6 February 2008 (Poster #715).
   Google Scholar
• Ladell K, Hellerstein MK, Cesar D, Busch R, Boban D, McCune JM. Central memory CD8+ T cells appear to have a shorter lifespan and reduced abundance as a function of HIV disease progression. J. Immunol.180(12), 7907–7918 (2008).
   PubMedGoogle Scholar
• van Lunzen J, Pollard R, Stellbrink HJ et al. DermaVir for initial treatment of HIV-infected subjects demonstrates preliminary safety, immunogenicity and HIV-RNA reduction versus placebo immunization. Presented at: XVIII International AIDS Conference. Vienna, Austria (2010) (Abstract #A-240-0111-12561).
   Google Scholar
• Rodriguez B, Asmuth D, Matining R et al. Repeated-dose transdermal administration of DermaVir, a candidate plasmid DNA-based therapeutic HIV vaccine, is safe and well-tolerated: a 61-week analysis of ACTG Study 5176. Presented at: XVIII International AIDS Conference. Vienna, Austria (2010) (Abstract # A-240-0111-10145).
   Google Scholar
• Katlama C, Ingrand D, Loveday C et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA276(2), 118–125 (1996).
   PubMed Web of Science ®Google Scholar
• Vidal C, Garcia F, Gatell JM et al. Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV-1-infected patients. J. Acquir Immune Defic Syndr. Hum. Retrovirol19(1), 55–60 (1998).
   Google Scholar
• Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science271(5255), 1582–1586 (1996).
   PubMed Web of Science ®Google Scholar
• Davis BS, Chang GJ, Cropp B et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J. Virol.75(9), 4040–4047 (2001).
   PubMed Web of Science ®Google Scholar
• Garver KA, LaPatra SE, Kurath G. Efficacy of an infectious hematopoietic necrosis (IHN) virus DNA vaccine in Chinook Oncorhynchus tshawytscha and sockeye O. nerka salmon. Dis. Aquat Organ64(1), 13–22 (2005).
   PubMed Web of Science ®Google Scholar
• Thacker EL, Holtkamp DJ, Khan AS, Brown PA, Draghia-Akli R. Plasmid-mediated growth hormone-releasing hormone efficacy in reducing disease associated with Mycoplasma hyopneumoniae and porcine reproductive and respiratory syndrome virus infection. J. Anim Sci.84(3), 733–742 (2006).
   PubMed Web of Science ®Google Scholar
• Kitahata MM, Gange SJ, Abraham AG et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N. Engl. J. Med.360(18), 1815–1826 (2009).
   PubMed Web of Science ®Google Scholar